Spero Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Spero Therapeutics, Inc. (SPRO) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$34.79 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-05-10
- Spero Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$34.79M, a 196.57% decline year-over-year.
- Spero Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $61.91M.
- Spero Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was $36.02M.
- Spero Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was -$965.00K.
- Spero Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $76.97M, a 1564.64% increase from fiscal 2016.
- Spero Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $4.62M, a 14.92% decline from fiscal 2015.
- Spero Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $5.43M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$34.79M 10-Q · filed 2018-05-10 | $27.13M derived: sum of 2 quarters · filed 2018-05-10 | ||
| 2017-12-31 | $61.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $76.97M 10-K · filed 2018-04-02 | ||
| 2017-09-30 | $15.06M 10-Q · filed 2017-12-14 | |||
| 2017-03-31 | $36.02M 10-Q · filed 2018-05-10 | $35.06M derived: sum of 2 quarters · filed 2018-05-10 | ||
| 2016-12-31 | -$965.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $4.62M 10-K · filed 2018-04-02 | ||
| 2016-09-30 | $5.59M 10-Q · filed 2017-12-14 | |||
| 2015-12-31 | $5.43M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |